Jefferies Global Healthcare Conference: Transgene will give a corporate presentation on November 19. The conference will be held in London, UK.
Portzamparc Biotech Seminar: Transgene will meet with investors at this event, which is being held on November 25 in Paris, France.
German Equity Forum: Transgene will give a corporate presentation on November 25 at 4 PM CET. The conference will be held in Frankfurt, Germany.
The Company also announced that data from the Phase 2b part of the Phase 2b/3 TIME trial will be presented at two upcoming medical meetings in the US:
ASCO Chicago Multidisciplinary Symposium in Thoracic Oncology: Data will be presented in a poster entitled: TIME, a phase 2b/3 study evaluating TG4010 in combination with first line therapy in advanced non small cell lung cancer (NSCLC), Phase 2b results (Poster board #172). The symposium is being held October 30-November 1 in Chicago, Illinois.
Society for Immunotherapy of Cancer (SITC)'s 29th Annual Meeting: An oral presentation, TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): Phase 2b results of the TIME study, will be given by John Nemunaitis, MD, Executive Medical Director of Mary Crowley Cancer Research Centers on November 7. The meeting is being held in National Harbor, Maryland.
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||2.67 (c)||-0.74%||56 075|